SYN News and Press, Synthetic Biologics Inc.

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better ref...

ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fund...

Synthetic Biologics ( NYSE: SYN ) on Tuesday said a data safety board had recommended that its phase 1b/2a study of its SYN-004 therapy for the treatment of acute graft-versus-host-disease in stem cell transplant recipients could proceed to enroll patients into the second coho...

- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical...

Synthetic Biologics ( NYSE: SYN ) said VCN-01, in combination with AstraZeneca's Imfinzi (durvalumab), showed an acceptable safety profile and encouraging biological activity in patients with a type of head and neck cancer, as per initial data from a phase 1 trial. ...

-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developi...

Synthetic Biologics, Inc. (SYN) Q2 2022 Earnings Conference Call August 11, 2022 08:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief Financial Officer Manel Cascallo - General Director of VCN &...

Synthetic Biologics press release ( NYSE: SYN ): Q2 GAAP EPS of -$0.31. Cash and cash equivalents totaled $52.3M as of June 30, 2022, compared to $67.3M as of December 31, 2021. Cash balance as of August 1, 2022 of $53.5M, including the additional $3M in gross proceeds...

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- ...

Synthetic Biologics ( NYSE: SYN ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.30 (-1400.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 ...